Monocentric Results and Twenty Four Months Outcomes After Ranibizumab Treatment for Exsudative Age-Related Macular Degeneration

Purpose:To investigate the results of intravitreal ranibizumab injections for choroidal neovascularization (CNV) secondary to age-related macular degeneration after 24-months treatment. Methods:: Retrospectively analysis of all consecutive eyes with CNV secondary to AMD, who needed 1 intravitreal ranibizumab injection at least 24 months before. Best visual corrected visual acuity (BCVA) variations and central macular thickness (CMT) were analyzed from baseline (M0) to month 12 (M12) and month 24 (M24). Results:Ninety-six eyes of 79 patients (23 males, 56 females, and aged 63-90 years) were selected for the study. The number of ranibizumab intravitreal injections administrated fluctuated from single to 16. Mean BCVA improved by 9 letters from M0 to M12 significantly (p<0.001) and maintained at 7 letters to M24 (p<0.001). Precisely at M12 and M24, 91 eyes (94.8%) and 84 eyes 587.5%) lost fewer than 15 letters, 25 eyes (26%) and 24 eyes (25%) improved by 15 letters, 5 eyes (5.2%) and 12 eyes (12.5%) decreased more than 15 letters. OCT modifications (sub-retinal fluid, cystoid macular oedema and epithelium detachment decreased between M0 and M24 (delta: 20, 30 and 41 respectively). Conclusions:Our study was similar to other studies and intravitral ranibizumab was effective on BCVA and OCT exsudative signs requiring variable regimen over 24 months.